Capivasertib is a potent, selective pan-AKT inhibitor categorized as a kinase inhibitor that targets AKT1, AKT2, and AKT3 isoforms. By blocking these serine/threonine protein kinases, this therapeutic… Read more

















![Chemical structure of tert-Butyl (S)-(4-((1-(4-chlorophenyl)-3-hydroxypropyl)carbamoyl)-1-(7-nitroso-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl)carbamate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2Ftert-Butyl-S-4-1-4-chlorophenyl-3-hydroxypropylcarbamoyl-1-7-nitroso-7H-pyrrolo23-dpyrimidin-4-ylpiperidin-4-ylcarbamate.png&w=3840&q=75)
![Chemical structure of tert-Butyl (S)-4-(4-((tert-butoxycarbonyl)amino)-4-((1-(4-chlorophenyl)-3-hydroxypropyl)carbamoyl)piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-7-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F3107819-50-8-tert-Butyl-S-4-4-tert-butoxycarbonylamino-4-1-4-chlorophenyl-3-hydroxypropylcarbamoylpiperidin-1-yl-7H-pyrrolo23-dpyrimidine-7-carboxylat.png&w=3840&q=75)
Capivasertib is a potent, selective pan-AKT inhibitor categorized as a kinase inhibitor that targets AKT1, AKT2, and AKT3 isoforms. By blocking these serine/threonine protein kinases, this therapeutic agent disrupts critical signaling pathways responsible for tumor cell proliferation, survival, and metabolism. It is primarily indicated for the treatment of adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, particularly in cases involving PIK3CA, AKT1, or PTEN gene alterations. Pharmaceutical laboratories utilize high-quality reference standards for Capivasertib, including its synthetic and degradative impurities, metabolites, and stable isotope labelled compounds, to support rigorous analytical testing and quality control. These materials are essential for accurate impurity profiling and method validation throughout the drug development and manufacturing lifecycle, ensuring the precision and consistency of quantitative analyses in complex clinical and research environments.